Stone in Yunfu: carving timeless beauty through centuries of craftsmanship
Yunfu, a city in Guangdong Province known as the "Capital of Stone in China," shines as a radiant pearl in the Lingnan region. Every piece of stone here bears the mark of time. With a legacy spanning over four centuries, Yunfu fuses the raw artistry of nature with the brilliance of human craftsmanship, creating a stone culture that has captivated the world.
Yunfu is home to a diverse collection of stone, resembling nature's grand palette and showcasing the "essence of global geological evolution". It boasts over a thousand varieties of stone, including marble, granite, and limestone, alongside internationally renowned stones such as Blue Jade from Africa, Crystal from Italy, Snow Mountain Blue, Pandora, Golden Peacock, and Crystal Blue from Brazil. As "China's Stone Circulation Demonstration Base" and "China's Capital of Artificial Stone," Yunfu hosts the annual International Stone Materials Science and Tech Fair and Stone Culture Week, drawing merchants from around the globe and living up to its promise of "global sourcing and global sales."
Yunfu hosts China's largest stone industry cluster, with over 4,000 enterprises stretching along the famed "Hundred-Mile Stone Materials Corridor" and 200,000 skilled professionals driving innovation. The simultaneous advancement of eco-friendly production and digital transformation has infused traditional industries with green vitality in the modern era.
Today, Yunfu connects with the world through stone. From monumental architectural visions to elegant touches in home design, the stone in Yunfu, carved with centuries of craftsmanship and infused with the spirit of nature, continues to create timeless masterpieces for the global stage.
The 22nd Yunfu International Stone Materials Sci-Tech Fair and the 16th Yunfu Stone Cultural Week will be held from October 18 to 21, 2025, at Hall A of the Yunfu International Stone Materials Expo Center at Hekou Subdistrict, Yuncheng District, Yunfu City.
This year, the event will feature stone pavilions of fine stone products showcased by stone enterprises. We sincerely invite fellow professionals, designers, and distinguished guests from around the world in the stone industry to participate as exhibitors or visitors.
Scan the QR codes to discover more about Yunfu's stone industry.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
6 hours ago
- Korea Herald
Stone in Yunfu: carving timeless beauty through centuries of craftsmanship
GUANGZHOU, China, Aug. 14, 2025 /PRNewswire/ -- News report from GDToday. Yunfu, a city in Guangdong Province known as the "Capital of Stone in China," shines as a radiant pearl in the Lingnan region. Every piece of stone here bears the mark of time. With a legacy spanning over four centuries, Yunfu fuses the raw artistry of nature with the brilliance of human craftsmanship, creating a stone culture that has captivated the world. Yunfu is home to a diverse collection of stone, resembling nature's grand palette and showcasing the "essence of global geological evolution". It boasts over a thousand varieties of stone, including marble, granite, and limestone, alongside internationally renowned stones such as Blue Jade from Africa, Crystal from Italy, Snow Mountain Blue, Pandora, Golden Peacock, and Crystal Blue from Brazil. As "China's Stone Circulation Demonstration Base" and "China's Capital of Artificial Stone," Yunfu hosts the annual International Stone Materials Science and Tech Fair and Stone Culture Week, drawing merchants from around the globe and living up to its promise of "global sourcing and global sales." Yunfu hosts China's largest stone industry cluster, with over 4,000 enterprises stretching along the famed "Hundred-Mile Stone Materials Corridor" and 200,000 skilled professionals driving innovation. The simultaneous advancement of eco-friendly production and digital transformation has infused traditional industries with green vitality in the modern era. Today, Yunfu connects with the world through stone. From monumental architectural visions to elegant touches in home design, the stone in Yunfu, carved with centuries of craftsmanship and infused with the spirit of nature, continues to create timeless masterpieces for the global stage. The 22nd Yunfu International Stone Materials Sci-Tech Fair and the 16th Yunfu Stone Cultural Week will be held from October 18 to 21, 2025, at Hall A of the Yunfu International Stone Materials Expo Center at Hekou Subdistrict, Yuncheng District, Yunfu City. This year, the event will feature stone pavilions of fine stone products showcased by stone enterprises. We sincerely invite fellow professionals, designers, and distinguished guests from around the world in the stone industry to participate as exhibitors or visitors. Scan the QR codes to discover more about Yunfu's stone industry.
Korea Herald
06-08-2025
- Korea Herald
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of AVTOZMA ® (tocilizumab-anoh) to include the treatment of cytokine release syndrome (CRS) in adults and pediatric patients aged 2 years and older. Following FDA approval of the additional indication for CRS, AVTOZMA IV now aligns with all indications approved for ACTEMRA ® IV in the United States. [1] Earlier this year, the FDA approved AVTOZMA as a biosimilar to ACTEMRA in IV formulations for the treatment of multiple diseases including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and coronavirus disease (COVID-19). [1] CRS is a potentially life-threatening condition that occurs when the immune system is highly activated, leading to the rapid and excessive release of cytokines into the bloodstream. During a cytokine storm, the overactivated immune system can cause widespread inflammation and damage to healthy tissue and organs throughout the body with symptoms ranging from mild, flu-like symptoms to more severe complications such as low blood pressure, difficulty breathing, and multi-organ failure. [2] "We are proud that AVTOZMA IV has now achieved full indication alignment with the reference ACTEMRA IV. This milestone marks an important step forward in our mission to deliver a safe and effective therapy for CRS," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. "This FDA approval expands access to high-quality biologics and supports beneficial patient outcomes across multiple therapeutic areas." In accordance with the patent settlement agreement with Genentech, the IV formulation of AVTOZMA is expected to be available in the U.S. on August 31, 2025. Celltrion holds a license to market the subcutaneous formulation in the U.S. commencing on the licensed launch date, which remains confidential. Notes to Editors: AVTOZMA ® (tocilizumab-anoh), containing the active ingredient tocilizumab, is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial designed to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of CT-P47 compared to reference tocilizumab. AVTOZMA received approval from the U.S. Food and Drug Administration (FDA) and European Commission (EC) in January and February 2025, respectively. INDICATION AVTOZMA ® (tocilizumab-anoh) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS INFECTIONS AVTOZMA ® and other tocilizumab products may increase the risk of serious infections, potentially leading to hospitalization or death, especially in patients using concurrent immunosuppressants. If a serious infection develops, interrupt AVTOZMA until the infection is controlled. Reported infections include: Monitor patients for signs of infection, including TB, during and after AVTOZMA treatment. Contraindications: Known hypersensitivity to tocilizumab products. Serious Infections. Serious and sometimes fatal infections have been reported with AVTOZMA. Do not use during active infections, including localized infections. Discontinue AVTOZMA if a serious infection occurs and resume only once controlled. Gastrointestinal (GI) Perforation. Gastrointestinal perforations, often linked to diverticulitis, have been reported with tocilizumab. Use AVTOZMA cautiously in high-risk patients and promptly evaluate new abdominal symptoms for early detection and management. Hepatoxicity. Monitor for hepatic injury signs. Avoid AVTOZMA if ALT/ AST >1.5x ULN (RA/GCA) or >10x ULN (COVID-19); discontinue if ALT/AST >5x ULN or symptoms of liver disease develop. Changes in Laboratory Parameters. Monitor neutrophils, platelets, liver enzymes, and lipids due to potential treatment-related changes; avoid initiating AVTOZMA in patients with critically low ANC or platelet counts. Immunosuppression. The impact of AVTOZMA on malignancy development is unknown, but it may increase risk as an immunosuppressant. Hypersensitivity Reactions, including anaphylaxis, and death, have occurred; administer IV infusions with anaphylaxis management support, discontinue permanently if reactions occur, and avoid use in patients with known hypersensitivity. Demyelinating Disorders. The impact of tocilizumab on demyelinating disorders is unknown, but rare cases were reported; monitor symptoms and use caution with preexisting or recent disorders. Active Hepatic Disease and Hepatic Impairment. Treatment with AVTOZMA is not recommended. Live Vaccines. Avoid concurrent use with AVTOZMA. Adverse Reactions (≥5%) include upper respiratory tract infections, nasopharyngitis, headache, hypertension, elevated ALT, and injection site reactions. About Celltrion Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion endeavors to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 countries. Celltrion has seven biosimilars approved by the U.S. FDA: INFLECTRA ® (infliximab-dyyb), TRUXIMA ® (rituximab-abbs), HERZUMA ® (trastuzumab-pkrb), VEGZELMA ® (bevacizumab-adcd), YUFLYMA ® (adalimumab-aaty), STEQEYMA ® (ustekinumab-stba), and AVTOZMA ® (tocilizumab-anoh), as well as novel biologic ZYMFENTRA ® (infliximab-dyyb). For more information, please visit Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", "anticipates", the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company's business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements. Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws.
Korea Herald
05-08-2025
- Korea Herald
Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advancing the Next Stage of Diagnostics
SEOUL, South Korea, Aug. 5, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics, unveiled two new technologies at ADLM 2025 in Chicago (July 29–31) designed to advance laboratory automation and data-driven infectious disease monitoring. The company introduced CURECA™, world's first fully unattended PCR automation system, and STAgora™, a real-time data analytics platform intended to support earlier detection and precision care. Chairman Highlights Next Step in Molecular Diagnostics "With CURECA™ and STAgora™, we are taking an important step toward the future of diagnostics," said Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, during a press conference with U.S. and global media on July 30. "Our goal is to enable laboratories worldwide to automate complex testing workflows and use diagnostic data more effectively, ultimately helping advance global efforts toward a world free from diseases." Today, most molecular testing systems remain only partially automated, dependent on skilled personnel for repetitive manual steps and fixed workflows that limit efficiency and scalability. CURECA™ Breaks the Limits of Automation to Reshape Global Diagnostics CURECA™ is the first system in the diagnostics industry designed to fully automate every step of PCR testing, including the traditionally manual pre-treatment stage. Seegene notes that achieving true full automation in diagnostics requires three key conditions: operation without highly trained professionals, continuous 24-hour processing, and uninterrupted specimen input. CURECA™ is designed to meet all three. Its dedicated module, CURECA™ Prep, processes a wide range of specimen types such as urine, blood, sputum, and stool, addressing one of the most persistent barriers to automation. With the module handling diverse specimen pre-treatment, the full CURECA™ system completes the entire PCR workflow from sample loading through nucleic acid extraction, amplification, and result analysis without manual intervention. The system is engineered for continuous 24-hour operation, aiming to minimize human error, improve workflow efficiency, and allow laboratories to allocate skilled staff to higher-value activities. Full automation has long been a challenge in diagnostics due to specimen variability and the reliance on trained personnel for repetitive pre-processing tasks. CURECA™ is intended to help laboratories overcome these constraints by providing a scalable and adaptable system that can be configured to fit different lab sizes and workflows. CURECA™ Prep could also potentially extend to other testing fields, such as clinical chemistry and immunodiagnostics, as Seegene continues to explore broader automation solutions. STAgora™ Transforms Diagnostic Data into Real-Time Clinical Intelligence STAgora™ is Seegene's latest platform, designed to collect and analyze PCR testing data in real time, providing laboratories with broader context to inform diagnostic workflows. The platform includes more than 40 analytical tools, offering functions such as infection trend tracking, hospital-level positivity monitoring, and multi-pathogen co-infection pattern analysis. Rather than serving as a simple data repository, STAgora™ is built as an integrated platform intended to help laboratories derive meaningful, aggregated insights from testing data. Today, individual test results often provide limited information without broader reference points. STAgora™ is designed to address this by enabling hospitals to build their own statistical datasets and compare aggregated data across institutions, helping them detect infection patterns faster and support more informed decision-making. The data shared through the platform is de-identified and formatted according to each institution's requirements, supporting secure, real-time exchange at local, national, or global levels. Advancing Toward a World Free from All Diseases Dr. Chun reiterated Seegene's long-term vision of building "a world free from diseases" noting that the introduction of CURECA™ and STAgora™ completes the company's five core technology pillars. These include Seegene's proprietary PCR technology, the SGDDS (Seegene Digitalized Development System) for automated assay development, its global Technology-Sharing Initiative, and now the addition of fully automated PCR testing and real-time data analytics capabilities. Industry experts at ADLM 2025 expressed strong interest in Seegene's new technologies. Jamel Giuma, President and CEO of Miami based laboratory IT consulting firm JTG Consulting Group, said, "I've attended many ADLM conferences over the years, and CURECA™ is one of the most innovative solutions I have seen so far. I believe it has the potential to simplify laboratory workflows, reduce the burden on lab personnel, and greatly enhance overall operational efficiency." "With CURECA™ and STAgora™, we're addressing long-standing barriers in molecular diagnostics," Dr. Chun added. "Just as smartphones and electric vehicles transformed their industries, we believe these technologies will redefine what is possible in diagnostic testing, helping laboratories worldwide achieve true automation, unlock the value of diagnostic data, and ultimately contribute to building a world free from diseases." Disclaimer CURECA™ and STAgora™ demonstrated at ADLM 2025 are pre-commercial technologies under development, not commercially available, and are not currently cleared for clinical diagnostic use in any jurisdiction.
